Mettler Toledo International targets 5% local currency growth in 2027, while its long-range plan points to mid-teens EPS growth and management expects China momentum to continue.
MTD · Mettler Toledo International Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Mettler Toledo reported 6% third-quarter growth and 13% EPS growth, with Asia Pacific and China each up 13%; it targets around 5% local currency revenue growth and low double-digit earnings growth in 2027, plus $950 million of repurchases.
The company reported U.S.-dollar sales increased 6% for both the three and nine months ended September 30, 2026, while nine-month gross margin reached 60.6%. Results included a one-time $52 million tariff refund benefit, partly offset by $28 million in customer refunds.
Mettler-Toledo International Inc. reported third-quarter local currency sales growth of 6%, Adjusted EPS of $12.57, up 13%, and raised full-year 2026 Adjusted EPS guidance to $47.70 to $47.90.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 31, 2026TL;DR. Mettler-Toledo reported strong Q2 results with local currency sales up 6% (above ~3% guidance) and adjusted EPS of $11.46, up 14%. The company raised full-year 2026 local currency sales growth guidance to ~4-5% and adjusted EPS growth to 10-11% (from prior 8-10%), while also lifting share repurchases to $875 million.
- + Raised full-year 2026 local currency sales growth guidance to approximately 4-5% from prior approximately 4%
- + Raised full-year 2026 adjusted EPS growth guidance to 10-11% from prior 8-10%
- + Q2 local currency sales grew 6%, above prior guidance of approximately 3%, with organic local currency growth of 4%
- + Adjusted EPS of $11.46 rose 14% year-over-year
- + Adjusted operating margin expanded 50 basis points to 29.3%, or up 100 basis points excluding currency
- + Increased full-year share repurchases to $875 million from an annualized $825 million level in the first half
- − Reported Americas sales declined 3% in U.S. dollars in Q2
- − Product inspection organic sales growth was only 1% in the quarter due to timing of customer projects
- − A $28 million one-time refund to customers reduced reported net sales by 3% in Q2
- − Year-to-date adjusted free cash flow of $367 million was negatively impacted by $55 million of higher tax payments versus prior year
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Local currency net sales to external customers excluding acquisitions growth | 5% | the three months ended June 30, 2026 filing | — |
| Organic local currency industrial net sales | 3% | the three months ended June 30, 2026 filing | — |
| Organic local currency laboratory net sales growth non-GAAP | 4% | the three months ended June 30, 2026 filing | — |
| Organic local currency net sales non-GAAP | 4% | the three months ended June 30, 2026 filing | — |
| Organic local currency service net sales growth non-GAAP | 7% | the three months ended June 30, 2026 filing | — |
| Segment profit | 333.9M | the three months ended June 30, 2026 filing | — |
| Service net sales growth (including spare parts), U.S. dollars | 10% | the three months ended June 30, 2026 filing | — |
| Total net sales growth in local currency | 10% | the three months ended June 30, 2026 filing | — |
| Adjusted EPS non-GAAP | $20.35 | six months ended June 30, 2026 | — |
| Adjusted free cash flow non-GAAP | $366.72M | Six months ended June 30, 2026 | — |
| Adjusted Operating Profit non-GAAP | $555.6M | six months ended June 30, 2026 | — |
| Local currency sales growth | 3% | Three months ended June 30, 2026 | — |
| Local currency sales growth excluding one-time tariff refunds | 6% | Three months ended June 30, 2026 | — |
| Organic local currency net sales growth | 3% | Six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MTD
this stock
Mettler Toledo International Inc
|
$34.36B | +23.9% | +4.0% | 37.5 | 3.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$256.15B | +19.3% | +14.5% | 36.5 | 1.3% |
|
DHR
Danaher Corp
|
$161.75B | +0.4% | +8.5% | 37.6 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.20B | +3.6% | +10.4% | 47.2 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$48.75B | +27.1% | +6.4% | 34.0 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 18
Mettler Toledo International targets 5% local currency growth in 2027, while its long-range plan points to mid-teens EPS growth and management expects China momentum to continue.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MTD | -2.0% | +6.3% | +57.9% | +3.1% | +23.9% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -0.3% | +9.7% | +59.3% | +5.2% | +15.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.